Thomas Taapken
CFO
Management
Medigene
Sweden
Biography
Dr. Thomas Taapken started as Medigene's CFO in January 2017. Before that, Dr. Taapken spent more than five years at Epigenomics AG, initially as CFO and subsequently, from October 2012, as its CEO/CFO. He then led the company’s efforts in gaining regulatory approval for the first blood-based molecular diagnostic cancer screening test by the FDA and oversaw its subsequent introduction into the US market. Before his time at Epigenomics, Dr. Taapken served as CFO at Biotie Therapies Corp. (now Acorda Therapeutics) and its predecessor companies for six years. His extensive international experience in the life sciences industry also includes over seven years as a venture capital investor at DVC Deutsche Venture Capital and San Francisco-based US venture capital firm Burrill & Company. Prior to that, he worked several years at Sanofi (originally Hoechst AG) in the United States and Germany, managing corporate venture capital activities, as well as in the areas of corporate & business development and research. Throughout his career, Dr. Taapken has been involved in numerous transactions spanning acquisitions, mergers and divestitures and helped to raise over EUR 100m through private and public offerings for those companies where he served in executive positions.
Research Interest
Blood-based molecular diagnostic cancer screening test by the FDA
